Auto saved by Logseq

pages/STOP2030___Annual Meeting___2024___Notas.md

@@ -10,4 +10,4 @@
 - [[Abraham Oduro]]: Director of Research for GHS. WP2. Dr Opare is the program manager for NTDs. We implement all the policies of the ministry. When I speak I do it for the director general. Division for R&D. We have the needed support to succeed. I wish everybody well and we're here to contribute positively.
 - [[Joseph Opare]]: we're privileged to be part of this consortium. We continue to have this infection. We've treated this condition for more than 15 years. Multifaceted approach. Happy to be part of this consortium.
 - PPB: She's not a director. The previous speakers have spoken. I have the written speach from the director. National drug regulatory authority. We're involved in RCT were we try to get the input of the scientists. One of our mandates is to have products with quality, efficacious and safe. When it is needed, it has to be available. When a product is licensed by the PPB. Ghana people, we privileged to have you. We're in touch with the Ghana FDA, we have counterparts. We can consult with them. For a long time alb and mlb. The need for repeated dosing. The one health guideline development group recomended further research in alternative antihelminthic medication or combination to avoid resistance development. The prooposed fdc of alb/ivm represents a promising advancement for those ailed by this disease. the ppb is commited to: 1: ensure that all mediciens approved meet the highest standards of safety, efficacy and quality. we'll evaluate the fdc to ensure that it meets those standards. 2) We appreciate your RCT your expertise we pledge to mantain transparency in this process keeping all stakeholders engaged. postmarket surveillance to ensure ongoing safety and efficacy. I reiterate the board commitment to improve public health through the approval and disemination of safe and effective medicines. we can improve the lifes of millions in kenya and globally. we're particularly optimistic about this initiative.
-- [[Doris Njomo]]: ESACIPAC has been conducting research about the program for STH. Mantain an evidence based approach. There has been a significar reduction at baseline STH. we're approaching the <2%. However this reduction is only to los 3. Due to the resistance of Strongy and Trichuris. They don't respond effectively to alb. It can be a gamechanger and a promising intervention for the WHO goals.
+- [[Doris Njomo]]: ESACIPAC has been conducting research about the program for STH. Mantain an evidence based approach. There has been a significar reduction at baseline STH. we're approaching the <2%. However this reduction is only to los 3. Due to the resistance of Strongy and Trichuris. They don't respond effectively to alb. It can be a gamechanger and a promising intervention for the WHO goals. We still have a lot of work to do. But treatment of SAC is the entry point. Also represent the director general of KEMRI. I'm going to read